Showing results (31-40 of 75) with videos related to
Sort By:
Pageof 8
Molecular Cancer Therapeutics|June 11, 2009
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicityHuw D Thomas, Kappusamy Saravanan, Lan-Zhen Wang, et al.The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicityMelissa L Fishel, David R Newell, Roger J Griffin, et al.Journal of Medicinal Chemistry|September 17, 2004
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoproteinNicola J Curtin, Hannah C Barlow, Karen J Bowman, et al.British Journal of Cancer|August 17, 2016
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerGary Beale, Emma J Haagensen, Huw D Thomas, et al.Molecular Cancer Therapeutics|September 20, 2005
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulationMarzia Pennati, Allyson J Campbell, Maria Curto, et al.Molecular Cancer Therapeutics|March 17, 2007
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trialHuw D Thomas, Christopher R Calabrese, Michael A Batey, et al.Chemical Biology & Drug Design|November 13, 2014
Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping ApproachAndrey Zaytsev, Barry Dodd, Matteo Magnani, et al.International Journal of Cancer|December 12, 2018
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastomaLindi Chen, Fabio Pastorino, Philip Berry, et al.Oncotarget|June 22, 2016
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationCatherine J Drummond, Arman Esfandiari, Junfeng Liu, et al.Plos One|October 12, 2012
Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancerKelly Coffey, Timothy J Blackburn, Susan Cook, et al.Pageof 8